EGFR-Mutated Lung Cancer With T790M-Acquired Resistance in the Brain and Histologic Transformation in the Lung

This case report describes the rare occurrence of a T790M resistance mutation found in a central nervous system (CNS) parenchymal metastasis. A concomitant squamous histology transformation in a lung non–T790M-resistant metastasis is also described. The authors hypothesize that this CNS resistance and histology transformation may have resulted from intermittent use of erlotinib treatment. This case report emphasizes the complexities of using erlotinib in the induction setting.

Target Audience

This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Explain a potential resistance mechanism to EGFR-TKI therapy when used to treat adenocarcinoma of the lung
  • Discuss CNS metastases in patients receiving TKI therapy
Additional information
Supporters: 

No commercial support was received for this article.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician
Course opens: 
09/19/2013
Course expires: 
09/19/2014
Cost:
$0.00

Kevin  S. Scher, MD
City of Hope Comprehensive Cancer Center
Duarte, California

Juan-Sebastian Saldivar, MD
City of Hope Comprehensive Cancer Center
Duarte, California

Michael Fishbein, MD
David Geffen School of Medicine at UCLA
Los Angeles, California

Alberto Marchevsky, MD
Cedars Sinai Medical Center
Hollywood, California

Karen L. Reckamp, MD
City of Hope Comprehensive Cancer Center
Duarte, California

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing